Valuation: Photocure ASA

Market Cap 131.89Cr 14Cr 12Cr 12Cr 10Cr 20Cr 1.33TCr 20Cr 137.95Cr 53Cr 678.58Cr 52Cr 51Cr 2.18TCr P/E 2026 *
17.6x
P/E 2027 * 63.8x
Enterprise Value 114.99Cr 12Cr 11Cr 10Cr 9.11Cr 17Cr 1.16TCr 17Cr 120.27Cr 46Cr 591.63Cr 45Cr 44Cr 1.9TCr EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.74x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-5.99%
Current month-5.99%
1 month-5.99%
3 months-8.58%
6 months-20.08%
Current year-19.29%
1 month 5.65
Extreme 5.65
5.65
Current year 5.65
Extreme 5.65
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
12.61
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 01/11/2018
Chief Tech/Sci/R&D Officer - 01/08/2021
Human Resources Officer - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/01/2022
Chairman - 27/09/2023
Director/Board Member - 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-5.99%0.00% - - 14Cr
+0.23%+1.97%+63.50%+118.18% 1,05500Cr
+0.34%+0.86%+49.65%+73.25% 65TCr
+0.94%+0.95%+19.64%+75.37% 47TCr
-1.36%-2.58%+38.77%+42.33% 35TCr
+1.34%+4.53%+22.56%+29.55% 27TCr
-0.48%-0.54%+12.66%+13.50% 26TCr
+0.82%+6.47%+52.78%+54.56% 22TCr
+0.87%+1.29%+35.41%+102.20% 19TCr
-0.30%-2.98%-28.24%-61.28% 17TCr
Average -0.33%+0.74%+29.64%+49.74% 40.43TCr
Weighted average by Cap. +0.30%+1.32%+39.92%+70.09%

Financials

2026 *2027 *
Net sales 66Cr 6.91Cr 6.08Cr 5.75Cr 5.22Cr 9.8Cr 663.78Cr 9.85Cr 69Cr 27Cr 338.71Cr 26Cr 25Cr 1.09TCr 67Cr 7Cr 6.16Cr 5.82Cr 5.28Cr 9.92Cr 671.85Cr 9.97Cr 70Cr 27Cr 342.83Cr 26Cr 26Cr 1.1TCr
Net income 7.63Cr 80.18L 70.52L 66.68L 60.48L 1.14Cr 77Cr 1.14Cr 7.98Cr 3.08Cr 39Cr 3.01Cr 2.95Cr 126.2Cr 2.1Cr 22.06L 19.4L 18.34L 16.64L 31.25L 21Cr 31.43L 2.2Cr 84.83L 11Cr 82.81L 81.02L 35Cr
Net Debt -17Cr -1.78Cr -1.56Cr -1.48Cr -1.34Cr -2.51Cr -170.4Cr -2.53Cr -18Cr -6.83Cr -87Cr -6.66Cr -6.52Cr -279.41Cr -16Cr -1.65Cr -1.45Cr -1.37Cr -1.24Cr -2.34Cr -158.3Cr -2.35Cr -16Cr -6.34Cr -81Cr -6.19Cr -6.06Cr -259.57Cr
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
49.80NOK
Average target price
79.67NOK
Spread / Average Target
+59.97%

Quarterly revenue - Rate of surprise